Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 9:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 76 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo matching Moxifloxacin Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

This Study Will Investigate the Effect of Single Oral Doses of Retosiban on Cardiac Repolarization, With Moxifloxacin as a Positive Control in Healthy Volunteers.

NCT01702376
View directory record Official record
Conditions
Obstetric Labour, Premature
Interventions
Retosiban 100 mg, Retosiban 800 mg, Placebo, Moxifloxacin 400 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 7, 2026, 9:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy Participants

NCT05630274
View directory record Official record
Conditions
Healthy
Interventions
Selpercatinib, Moxifloxacin, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 7, 2026, 9:57 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluation of Whether Deferiprone Affects QT Interval in Healthy Subjects

NCT01860703
View directory record Official record
Conditions
Prolonged QTc Interval
Interventions
Deferiprone, deferiprone matching placebo tablets, moxifloxacin, placebo
Drug
Lead sponsor
ApoPharma
Industry
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 12, 2014 · Synced Oct 7, 2026, 9:57 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants

NCT05046132
View directory record Official record
Conditions
Healthy
Interventions
Setmelanotide, Moxifloxacin, Oral Placebo, SC Placebo
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 7, 2026, 9:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Hydrocodone Bitartrate (HYD) Extended-Release Tablets on QT /QTc Intervals in Healthy Adult Subjects

NCT02243241
View directory record Official record
Conditions
Healthy
Interventions
HYD, Moxifloxacin, Placebo for HYD, Placebo for moxifloxacin
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 50 Years
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Oct 7, 2026, 9:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers

NCT04019652
View directory record Official record
Conditions
Hypertension, Mineralocorticoid Receptor Antagonist
Interventions
CS-3150, Moxifloxacin, Placebo matching moxifloxacin tablet, Placebo matching CS-3150
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 45 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Oct 7, 2026, 9:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval

NCT05924815
View directory record Official record
Conditions
Healthy Participants
Interventions
Aficamten, Aficamten-matching Placebo, Moxifloxacin
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 45 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Oct 7, 2026, 9:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared to Placebo and Moxifloxacin

NCT01756495
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Losmapimod, Moxifloxacin, Losmapimod matched Placebo, Moxifloxacin Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Oct 7, 2026, 9:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects

NCT06161220
View directory record Official record
Conditions
Cardiac Repolarization in Healthy Subjects
Interventions
Carbidopa capsule, Moxifloxacin Tablets, USP, Placebo
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Dilworth, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Oct 7, 2026, 9:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Participants

NCT02735603
View directory record Official record
Conditions
Heart Repolarization
Interventions
Naltrexone HCl/bupropion HCl, Placebo, Moxifloxacin
Drug · Other
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Oct 7, 2026, 9:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Single Oral Dose Dapagliflozin QT Study

NCT00688493
View directory record Official record
Conditions
Healthy
Interventions
Dapagliflozin, Moxifloxacin, Placebo to match moxifloxacin and dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 21, 2012 · Synced Oct 7, 2026, 9:57 PM EDT
Completed Phase 3 Interventional Results available

BAY12-8039: 5 Days for Sinusitis vs Placebo

NCT00492024
View directory record Official record
Conditions
Sinusitis
Interventions
Moxifloxacin (Avelox, BAY12-8039), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
51
States / cities
Birmingham, Alabama • Northport, Alabama • Jonesboro, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Oct 7, 2026, 9:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Tucatinib on Cardiac Repolarization in Healthy Participants

NCT03777761
View directory record Official record
Conditions
Healthy
Interventions
tucatinib, placebo, moxifloxacin
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2019 · Synced Oct 7, 2026, 9:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Effect of WCK 5222 on the QT/QTc Interval in Healthy Volunteers

NCT03554304
View directory record Official record
Conditions
QT/QTc Interval in Healthy Volunteers
Interventions
WCK 5222, IV placebo matched to WCK 5222 / Moxifloxacin IV solution, Moxifloxacin 400-mg
Drug
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Oct 7, 2026, 9:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Electrocardiogram Results in Healthy Volunteers Receiving Canagliflozin (JNJ-28431754)

NCT01787357
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin (JNJ-28431754), Placebo, Moxifloxacin
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 29, 2016 · Synced Oct 7, 2026, 9:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Effects of CBP-307 on the Heart Rate-corrected QT Interval (QTc) in Healthy Subjects

NCT04818229
View directory record Official record
Conditions
Autoimmune Diseases
Interventions
CBP-307, Placebo-matched CBP-307, Moxifloxacin (Avelox), Placebo-matched Moxifloxacin
Drug
Lead sponsor
Connect Biopharma Australia Pty Ltd
Industry
Eligibility
18 Years to 60 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Oct 7, 2026, 9:57 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban

NCT02213029
View directory record Official record
Conditions
Embryo Transfer
Interventions
Epelsiban, Placebo, Oxytocin, Ortho-Cylcen (21)® tablet
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Oct 7, 2026, 9:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study on the Effect of Etavopivat on Heart Rhythm in Healthy Participants

NCT07023029
View directory record Official record
Conditions
Healthy Volunteers, Sickle Cell Disease, Thalassemia
Interventions
Etavopivat, Moxifloxacin, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 7, 2026, 9:57 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Oral Nafithromycin in CABP

NCT02903836
View directory record Official record
Conditions
Community-Acquired Bacterial Pneumonia (CABP)
Interventions
Nafithromycin 800 mg 3 days, Nafithromycin 800 mg 5 days, Moxifloxacin 400 mg
Drug
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
Miami, Florida • Miami Lakes, Florida • Bedford, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2019 · Synced Oct 7, 2026, 9:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine the Effect of BMS-791325 on the ECG QTcF Interval in Healthy Subjects

NCT02084953
View directory record Official record
Conditions
Hepatitis C
Interventions
BMS-791325, Moxifloxacin, Placebo matching BMS-791325
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 49 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2014 · Synced Oct 7, 2026, 9:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single-Dose, Randomized, Placebo- and Active-Control, Four-Way, Cross-Over Study for the Evaluation of the Effect of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) on the QT/QTc Intervals in Adult Healthy Subjects

NCT04238195
View directory record Official record
Conditions
TQT Study
Interventions
Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) + Placebo, Moxifloxacin 400mg, Placebo for Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr), Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)
Drug · Other
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 13, 2020 · Synced Oct 7, 2026, 9:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Electrocardiographic Effects of Ponesimod in Healthy Male and Female Subjects

NCT02136888
View directory record Official record
Conditions
Healthy
Interventions
Ponesimod Placebo, Moxifloxacin Placebo, Ponesimod 10 mg, Ponesimod 20 mg, Ponesimod 40 mg, Ponesimod 60 mg, Ponesimod 80 mg, Ponesimod 100 mg, Moxifloxacin 400 mg
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 45 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Oct 7, 2026, 9:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult Participants

NCT04867980
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ACP-196, Moxifloxacin 400 mg, Placebo
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 30, 2021 · Synced Oct 7, 2026, 9:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.

NCT07272629
View directory record Official record
Conditions
Cardiac Repolarization, Healthy Volunteers
Interventions
Balinatunfib, Moxifloxacin, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 7, 2026, 9:57 PM EDT